RxDoctor Payments Data

Gerald Williams, DO

Internal Medicine · Kansas City, MONPI 1982695987

Payments from drug & device makers

$2,965in general payments, 2019–2025

Across 187 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$477
  • Lilly USA, LLC$404
  • Pfizer$311
  • Novo Nordisk$290
  • Amgen$244
  • AbbVie$202
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$2,94999%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,965 in reported general payments places this provider in the 80th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$24,735
Medicare patients
68
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide87$105,593
FarxigaDapagliflozin Propanediol44$51,552
JardianceEmpagliflozin38$47,226
EliquisApixaban41$37,159
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$15,141
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,038
RestasisCyclosporine11$6,863
Varenicline Tartrate33$6,172
Gabapentin227$4,276
Ezetimibe202$3,834
Celecoxib70$3,426
Rosuvastatin Calcium135$2,853
Omeprazole120$2,678
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate14$2,237
Atorvastatin Calcium243$1,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$290$105,59387 claims
AstraZenecaFarxiga, Breztri Aerosphere$477$60,59058 claims
Boehringer IngelheimJardiance$44$47,22638 claims
PfizerEliquis$311$37,15941 claims
GSKTrelegy Ellipta$70$15,14115 claims
AbbVieRestasis$202$6,86311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →